Innovent Biologics : INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON SALES OF TYVYT (SINTILIMAB INJECTION) IN THE FIRST QUARTER OF 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON SALES OF TYVYT® (SINTILIMAB INJECTION) IN THE FIRST QUARTER OF 2021

This announcement is made by Innovent Biologics, Inc. (the "Company", together with its subsidiaries, the "Group") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The revenue attributable to sales of TYVYT® (sintilimab injection), which is co-developed by the Group and Eli Lilly and Company and was successfully launched in March 2019, in the first quarter of 2021, was above RMB700 million.

In 2021, the Company has continued to leverage the early mover advantage of TYVYT® (sintilimab injection) as the first PD-1 product included in the National Reimbursement Drug List. The Company have continued to expand the network coverage of TYVYT® (sintilimab injection) in different tiers of cities and hospitals, adapt comprehensive and competitive marketing strategy, and expand the sales and promotion team. In the first quarter of 2021, TYVYT® (sintilimab injection) has kept achieving encouraging performance with continuous quarter over quarter growth trend on the sales volume since launched. The Company believes that the encouraging performance shows the strong market potential of TYVYT® (sintilimab injection) in China and the Company's commercialization capability as a high-quality manufacturer.

In February 2021, TYVYT® (sintilimab injection) was approved for the second indication in combination with chemotherapy as the first line treatment for non-squamousnon-small cell lung cancer ("NSCLC"). Besides, three more supplemental New Drug Application for TYVYT® (sintilimab injection) were under regulatory review with expected approval during 2021 to early 2022, including the first line treatment for squamous NSCLC, the first line treatment for hepatocellular carcinomas, and the second line treatment for squamous NSCLC. The Company expects TYVYT® (sintilimab injection) could benefit broader patient groups in 2021.

1

The financial information relating to TYVYT® (sintilimab injection) set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board

Innovent Biologics, Inc.

Dr. De-Chao Michael Yu

Chairman and Executive Director

Hong Kong, China, 27 April 2021

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, Mr. Shuyun Chen as Non-executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu and Dr. Kaixian Chen as Independent Non-executive Directors.

2